---
title: "AnaptysBio, Inc. (ANABV.US)"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ANABV.US.md"
symbol: "ANABV.US"
name: "AnaptysBio, Inc."
industry: "生物技術"
datetime: "2026-04-15T15:55:29.764Z"
locales:
  - [en](https://longbridge.com/en/quote/ANABV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ANABV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ANABV.US.md)
---

# AnaptysBio, Inc. (ANABV.US)

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 官網 | [www.anaptysbio.com](https://www.anaptysbio.com) |

## 關鍵驅動因素
> *AI 分析的影響該股票表現的關鍵因素*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Longbridge 獨家多因子評級模型*
> 更新時間: 2026-04-15T04:30:15.000Z

**綜合: C (0.54)**

**行業**: 生物技術

| 指標 | 數值 |
|--------|-------|
| 行業排名 | 118 / 393 |
| 行業中位數 | C |
| 行業均值 | C |

- **風格**: 成長型 - 公司主要業務處在成長期的股票。
- **規模**: 小盤型 - 公司經營有較高的成長性和波動性，易於獲得較高的投資收益。

**綜合評分**: C

#### 風格得分 評分: 

| 指標 | 數值 | 評級 |
|-----------|-------|--------|
| 營業收入同比 | 157.01% |  |
| 凈利潤同比 | 90.89% |  |
| 市凈率 | 35.15 |  |
| 股息率 | 0.00% |  |

#### 規模得分 評分: 

| 指標 | 數值 | 評級 |
|-----------|-------|--------|
| 市值 | 1308045602.50 |  |
| 營業收入 | 234603000.00 |  |

#### 多維評分 評分: C

| 指標 | 數值 | 評級 |
|-----------|-------|--------|
| 凈資產收益率（ROE） | -24.49% | E |
| 凈利率 | -5.64% | D |
| 毛利率 | 42.04% | B |
| 營業收入同比 | 157.01% | A |
| 凈利潤同比 | 90.89% | A |
| 總資產同比 | -24.69% | E |
| 凈資產同比 | -47.49% | E |
| 現金流凈利率 | -148.86% | E |
| 運營現金流同比 | 157.01% | A |
| 資產周轉率 | 0.55 | C |
| 資產負債率 | 89.79% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AnaptysBio, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "風格得分",
      "grade": "",
      "indicators": [
        {
          "name": "營業收入同比",
          "value": "157.01%",
          "rating": ""
        },
        {
          "name": "凈利潤同比",
          "value": "90.89%",
          "rating": ""
        },
        {
          "name": "市凈率",
          "value": "35.15",
          "rating": ""
        },
        {
          "name": "股息率",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "規模得分",
      "grade": "",
      "indicators": [
        {
          "name": "市值",
          "value": "1308045602.50",
          "rating": ""
        },
        {
          "name": "營業收入",
          "value": "234603000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "多維評分",
      "grade": "C",
      "indicators": [
        {
          "name": "凈資產收益率（ROE）",
          "value": "-24.49%",
          "rating": "E"
        },
        {
          "name": "凈利率",
          "value": "-5.64%",
          "rating": "D"
        },
        {
          "name": "毛利率",
          "value": "42.04%",
          "rating": "B"
        },
        {
          "name": "營業收入同比",
          "value": "157.01%",
          "rating": "A"
        },
        {
          "name": "凈利潤同比",
          "value": "90.89%",
          "rating": "A"
        },
        {
          "name": "總資產同比",
          "value": "-24.69%",
          "rating": "E"
        },
        {
          "name": "凈資產同比",
          "value": "-47.49%",
          "rating": "E"
        },
        {
          "name": "現金流凈利率",
          "value": "-148.86%",
          "rating": "E"
        },
        {
          "name": "運營現金流同比",
          "value": "157.01%",
          "rating": "A"
        },
        {
          "name": "資產周轉率",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "資產負債率",
          "value": "89.79%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## 估值分析

| 指標 | 當前值 | 行業排名 | 最高 | 中位 | 最低 |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -98.85 | 550/393 | - | - | - |
| PB | 35.15 | 435/393 | - | - | - |
| PS (TTM) | 5.58 | 113/393 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## 同業比較

| 排名 | 名稱 | 盈利 | 成長 | 營運 | 財務安全 | 現金流 | 評級 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel制藥 (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | 福泰制藥 (VRTX.US) | A | B | C | B | C | B |

## 參考連結

- [公司概況 — 簡介、高管、股東、業務構成](https://longbridge.com/zh-HK/quote/ANABV.US/overview.md)
- [財務報表 — 損益表、資產負債表、現金流、分紅方案](https://longbridge.com/zh-HK/quote/ANABV.US/norm.md)
- [相關新聞](https://longbridge.com/zh-HK/quote/ANABV.US/news.md)
- [公告 — 公司公告與監管文件](https://longbridge.com/zh-HK/quote/ANABV.US/filings.md)

---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**